A Study of SHR6390 Combined With Famitinib in the Treatment of ER + / HER2- Advanced Breast Cancer

NCT05103826 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

3

Enrollment

INDUSTRY

Sponsor class

Stopped Sponsor R \& D Strategy Adjustment

Conditions

ER+ / HER2- Advanced Breast Cancer

Interventions

DRUG: SHR6390、Famitinib

Sponsor

Jiangsu HengRui Medicine Co., Ltd.